StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CALCBullishCorporate Developmentsnews
High materiality8/10

FDA clears path for Auxora dosing in KOURAGE; pancreatitis program feedback due in Q3 2026

Jun 24, 2026, 7:07 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

No FDA comments reduce immediate hold risk; near-term catalysts include continued dosing and Q3 2026 pancreatitis-program feedback; potential upside if pivotal-path progress remains on track.

AI summary

What happened, with direct paths to the underlying reporting

FDA reviewed CalciMedica's KOURAGE amendment and interim safety data, with no comments, allowing continued Auxora dosing. The March amendments address design issues and confirm SAEs are not drug-related, reducing setback risk and keeping a potential pancreatitis pivotal program on track for 3Q26.

  • FDA reviewed KOURAGE protocol amendment and interim safety data; no comments.
  • Enrollment pause in January 2026 lifted; no clinical hold.
  • March 2026 amendment refined inclusion criteria and stratification.
  • SAEs were not drug-related and align with prior Auxora data.
  • FDA no comments; expects pancreatitis pivotal program feedback in Q3 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event